|
Previously unseen switch regulates breast cancer response to estrogen
May 09, 2008A tiny modification called methylation on estrogen receptors prolongs the life of these growth-driving molecules in breast cancer cells, according to research by scientists at Emory University's Winship Cancer Institute.
The results are published in the May 9, 2008 issue of the journal Molecular Cell.
Most breast cancers contain estrogen receptors, which enable them to grow in the presence of the hormone estrogen. Their presence can determine whether tumors will respond to the estrogen-blocking drug tamoxifen.
The finding will help researchers sort out how mutations change the estrogen receptor's function and allow some breast cancers to resist tamoxifen, says Paula Vertino, PhD, associate professor of radiation oncology at Emory University School of Medicine.
"The problem is that a significant fraction of estrogen receptor positive tumors don't respond to tamoxifen," Vertino says. "Development of new drugs that interfere with the methylation of the estrogen receptor may be an alternative way to treat those tumors."
Until recently, scientists thought methylation enzymes acted only on DNA molecules or on histones, proteins that bundle DNA into spool-like packages. Methylation enzymes add tags called methyl groups to other molecules, influencing their ability to turn genes on or off.
Vertino and her colleagues found that one of the modification enzymes, called SET7, methylates a flexible part of the estrogen receptor. When they created breast cancer cells with reduced levels of SET7, the estrogen receptor molecules lasted only half as long and were less effective in turning on genes.
Vertino's team showed that a mutation in the estrogen receptor found in more aggressive breast tumors interferes with methylation in cells. Also, the methylation appears in exactly the same spot where another protein called BRCA1 adds a different kind of regulatory marking, and may block BRCA1's restrictive effects on the estrogen receptor.
Women who inherit a mutation in the gene that encodes BRCA1 have up to an 80 percent lifetime risk of developing breast cancer, several times the risk of those who don't have it, according to the National Cancer Institute. BRCA1 mutations are estimated to account for about a third of all inherited breast cancers and roughly 2-3 percent of all breast cancers.
Scientists are beginning to look for drugs that could modulate methylation enzymes. Vertino says that methylation probably affects several other proteins similar to the estrogen receptor.
"I expect this will be just the tip of the iceberg," she says. "Methylation may be just as common as other protein modifications, and even more complicated."
Emory University
The finding will help researchers sort out how mutations change the estrogen receptor's function and allow some breast cancers to resist tamoxifen, says Paula Vertino, PhD, associate professor of radiation oncology at Emory University School of Medicine.
"The problem is that a significant fraction of estrogen receptor positive tumors don't respond to tamoxifen," Vertino says. "Development of new drugs that interfere with the methylation of the estrogen receptor may be an alternative way to treat those tumors."
Until recently, scientists thought methylation enzymes acted only on DNA molecules or on histones, proteins that bundle DNA into spool-like packages. Methylation enzymes add tags called methyl groups to other molecules, influencing their ability to turn genes on or off.
Vertino and her colleagues found that one of the modification enzymes, called SET7, methylates a flexible part of the estrogen receptor. When they created breast cancer cells with reduced levels of SET7, the estrogen receptor molecules lasted only half as long and were less effective in turning on genes.
Vertino's team showed that a mutation in the estrogen receptor found in more aggressive breast tumors interferes with methylation in cells. Also, the methylation appears in exactly the same spot where another protein called BRCA1 adds a different kind of regulatory marking, and may block BRCA1's restrictive effects on the estrogen receptor.
Women who inherit a mutation in the gene that encodes BRCA1 have up to an 80 percent lifetime risk of developing breast cancer, several times the risk of those who don't have it, according to the National Cancer Institute. BRCA1 mutations are estimated to account for about a third of all inherited breast cancers and roughly 2-3 percent of all breast cancers.
Scientists are beginning to look for drugs that could modulate methylation enzymes. Vertino says that methylation probably affects several other proteins similar to the estrogen receptor.
"I expect this will be just the tip of the iceberg," she says. "Methylation may be just as common as other protein modifications, and even more complicated."
Emory University
Estrogen Receptor News and Current Estrogen Receptor Events RSSTreating osteoporosis calls for physician, dentist collaboration: ADA Journal
Physicians and dentists should collaborate to improve early detection and treatment of patients who have or may develop osteoporosis, say researchers in the cover story of the May issue of The Journal of the American Dental Association.
Treatment advances for fibroids, menopause
Women with fibroids and endometriosis facing the possibility of hysterectomy may now choose less invasive treatment options to preserve fertility, according to Yale professor Aydin Arici, M.D., who will direct a scientific session exploring these alternatives at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting May 3-7 in New Orleans, Louisiana.
A diagnosis of triple-negative breast cancer doesn't always mean cancer spread
Triple-negative breast cancers are a heterogeneous group and may not always be associated with lymph node spread, a new study shows.
Breast cancer subtypes linked to survival from secondary brain tumors
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases.
How DDT metabolite disrupts breast cancer cells
Research has shown that the main metabolite of the insecticide DDT could be associated with aggressive breast cancer tumours, but there has been no explanation for this observation to date. Now a report published in the open access journal Breast Cancer Research shows how DDT could act to disrupt hormone-sensitive breast cancer cells.
Benefit of cancer prevention surgery differs between women with BRCA1 and BRCA2 mutations
The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations.
Findings Point to Molecular 'Achilles Heel' for Half of Breast Cancer Tumors
Researchers at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center have shown why a protein known as cyclin D1 may be the Achilles heel for breast tumors that are estrogen receptor positive (ER+) − which is the most common type of breast cancer.
Chemotherapy and tamoxifen reduce risk of second breast cancer
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute. The risk reduction persisted for at least 10 and 5 years, respectively.
New computational technique can predict drug side effects
Early identification of adverse effects of drugs before they are tested in humans is crucial in developing new therapeutics, as unexpected effects account for a third of all drug failures during the development process.
Jefferson Scientists See Breast Cancer Gene Activity from Outside the Body
Researchers at Jefferson Medical College and Jefferson's Kimmel Cancer in Philadelphia have used PET imaging to see hyperactive cancer genes inside breast tumors in laboratory animals, marking the first time such gene activity has been observed from outside the body.
More Estrogen Receptor News Articles
| © 2008 BrightSurf.com |